Minimizing tuberculosis risk in patients receiving anti-TNF therapy

Annals of the American Thoracic Society

Volumn 14, Issue 5, 2017, Pages 621-623

  Esmail, Hanif ^a,b   Wilkinson, Robert J ^a,c,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

CELLULAR IMMUNITY; EDITORIAL; HIGH RISK POPULATION; HUMAN; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PREDICTIVE VALUE; RISK REDUCTION; SERODIAGNOSIS; TUBERCULIN TEST; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; HUMANS; LATENT TUBERCULOSIS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85018949454     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201701-055ED     Document Type: Editorial

References (18)

1. Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010;161:1-9.
2. Horsburgh CR Jr, Rubin EJ. Clinical practice: latent tuberculosis infection in the United States. N Engl J Med 2011;364:1441-1448.
3. Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-α treatments. Rheumatology (Oxford) 2005;44:1205-1206.
4. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med 2001;345:1098-1104.
5. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-1206.
6. Hou JK, Kramer JR, Richardson P, Sansgiry S, El-Serag HB. Tuberculosis screening and reactivation among a national cohort of patients with inflammatory bowel disease treated with tumor necrosis factor alpha antagonists. Inflamm Bowel Dis 2017;23:254-260.
7. Lee J, Kim E, Jang EJ, Lee CH, Lee EY, Im JP, Han SK, Yim JJ. Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist. Ann Am Thorac Soc 2017;14:690-697.
8. Lee SH. Diagnosis and treatment of latent tuberculosis infection. Tuberc Respir Dis (Seoul) 2015;78:56-63.
9. Kim ES, Song GA, Cho KB, Park KS, Kim KO, Jang BI, Kim EY, Jeon SW, Lee HS, Yang CH, et al. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents. World J Gastroenterol 2015;21:3308-3316.
10. Esmail H, Barry CE III, Young DB, Wilkinson RJ. The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci 2014;369:20130437.
11. Singanayagam A, Manalan K, Sridhar S, Molyneaux PL, Connell DW, George PM, Kindelerer A, Seneviratne S, Lalvani A, Wickremasinghe M, et al. Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy. Thorax 2013;68:955-961.
12. Bélard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, Thomsen H, Brylov A, Hetland ML, Nordgaard-Lassen I, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011;17:2340-2349.
13. Wirth T, Hildebrand F, Allix-Béguec C, Wölbeling F, Kubica T, Kremer K, van Soolingen D, Rüsch-Gerdes S, Locht C, Brisse S, et al. Origin, spread and demography of the Mycobacterium tuberculosis complex. PLoS Pathog 2008;4:e1000160.
14. Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, Hadziyannis E. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol 2011;18:2102-2108.
15. Gómez-Reino JJ, Carmona L, Angel Descalzo.; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-761.
16. Esmail H, Thienemann F, Oni T, Goliath R, Wilkinson KA, Wilkinson RJ. QuantiFERON conversion following tuberculin administration is common in HIV infection and relates to baseline response. BMC Infect Dis 2016;16:545.
17. Abitbol Y, Laharie D, Cosnes J, Allez M, Nancey S, Amiot A, Aubourg A, Fumery M, Altwegg R, Michetti P, et al.; GETAID. Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort. J Crohn's Colitis 2016;10:1179-1185.
18. Cobelens F, Kik S, Esmail H, Cirillo DM, Lienhardt C, Matteelli A. From latent to patent: rethinking prediction of tuberculosis. Lancet Respir Med 2016;pii:S2213-2600 (16) 30419-2.